Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy

Cancer

Volumn 115, Issue 11, 2009, Pages 2482-2490

  Quintás Cardama, Alfonso ^a   Kantarjian, Hagop ^a   Ravandi, Farhad ^a   O'Brien, Susan ^a   Thomas, Deborah ^a   Vidal Senmache, Gabriela ^b   Wierda, William ^a   Kornblau, Steven ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HOSPITAL NACIONAL EDGARDO REBAGLIATI MARTINS   (Peru)

Author keywords

Bleeding diathesis; Chronic myelogenous leukemia; Dasatinib; Management; Risk factors

Indexed keywords

DASATINIB; FIBRINOGEN; IMATINIB; PROTON PUMP INHIBITOR;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLEEDING TENDENCY; BLOOD TRANSFUSION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON BIOPSY; COLONOSCOPY; CORRELATION ANALYSIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; FIBRINOGEN BLOOD LEVEL; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; GINGIVA BLEEDING; HUMAN; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROTHROMBIN TIME; RASH; RISK FACTOR; SINGLE DRUG DOSE; THROMBOCYTOPENIA; VAGINA BLEEDING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMORRHAGIC DISORDERS; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; PIPERAZINES; PLATELET COUNT; PYRIMIDINES; RISK FACTORS; THIAZOLES; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 66649092089     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24257     Document Type: Article

References (22)

1. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652. (Pubitemid 34815868)
2. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004. (Pubitemid 36302244)
3. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 2000;289:1938-1942.
4. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 2003;101:690-698. (Pubitemid 36077594)
5. Donato NJ, Wu JY, Stapley J, et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. 2004;64:672-677. (Pubitemid 38120909)
6. Dai Y, Rahmani M, Corey SJ, Dent P, Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem. 2004;279:34227-34239. (Pubitemid 39318046)
7. Wu J, Meng F, Kong LY, et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst. 2008;100:926-939.
8. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-[2-hydroxyethyl]-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47:6658-6661. (Pubitemid 40053752)
9. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399-401. (Pubitemid 38938156)
10. Mauro M, Baccarani M, Cervantes F, et al. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) [abstract]. Proc Am Soc Clin Oncol. 2008;26:374s. Abstract 7009.
11. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531-2541. (Pubitemid 43882349)
12. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109:3207-3213. (Pubitemid 46572505)
13. Mustjoki S, Laurinolli T, Ekblom M, et al. Clonal large granular lymphocyte (LGL) expansion associated with dasatinib therapy [abstract]. Blood. 2007;110:863a. Abstract 2938.
14. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and - intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008;26:3204-3212.
15. Sprycel Scientific Discussion. Available at: http://209.85.165.104/ search?q=cache:KW1gSD1bwJQJ:www.emea.eu.int/humandocs/PDFs/EPAR/sprycel/ H-709-en6.pdf+dasatinib+and+bleeding&hl=en&gl=us&ct=clnk&cd=1. Accessed on November 17, 2007.
16. Wang K, Schumacher W. Effects of BMS-354825 on platelet function. BMS-Document Control No. 930004015. New York: Bristol-Myers Squibb Company; 2003.
17. Quintas-Cardama A, Han X, Kantarjian H, Cortes J. Dasatinib-induced platelet dysfunction [abstract]. Blood. 2007;110:864a. Abstract 2941.
18. Chen Z, Lee FY, Bhalla KN, Wu J. Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol. 2006;69:1527-1533.
19. Hellstrom M, Kalen M, Lindahl P, Abramsson A, Betsholtz C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development. 1999;126:3047-3055. (Pubitemid 29378170)
20. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 1997;277:242-245. (Pubitemid 27446080)
21. Kaminski WE, Lindahl P, Lin NL, et al. Basis of hematopoietic defects in platelet-derived growth factor (PDGF)-B and PDGF beta-receptor null mice. Blood. 2001;97:1990-1998. (Pubitemid 32239078)
22. Christopher LJ, Cui D, Wu C, et al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos. 2008;36:1357-1364.